REDWOOD CITY, Calif., May 26, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven Oncotype DX® studies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 3-7 at McCormick Place in Chicago. The results will include:
"Results from the latest breast and prostate cancer studies highlight the important impact of Oncotype DX in changing the treatment paradigm for hundreds of cancer patients every day," said Steven Shak, M.D., chief scientific officer, Genomic Health. "The breadth and strength of evidence for the clinical utility of Oncotype DX continue to be uniquely recognized by leading authorities in cancer. For example, the National Comprehensive Cancer Network (NCCN), in its updated breast cancer guidelines regarding node-negative and node-positive patients, specifically named Oncotype DX as the 'best validated' test for chemotherapy prediction."
The ASCO abstracts are now available at http://abstracts.asco.org/. Following are details for each presentation (all times are in Central Daylight Time):
Saturday, June 4
Sunday, June 5
Monday, June 6
About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With more than 600,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, one of the greatest issues in healthcare today. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid and tissue-based tests. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties are set forth in our filings with the Securities and Exchange Commission, including in our quarterly report on Form 10-Q for the quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
GHDX-B
Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
SOURCE Genomic Health, Inc.